Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide in Relapsed/Refractory T-Cell Non-Hodgkin's Lymphoma
NCT00655668Phase 2Terminated
- Sponsor
- Celgene Corporation
- Start
- Mar 2008
- Primary completion
- Mar 2010
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of lenalidomide in T-cell non-Hodgkin lymphoma, sponsored by Celgene Corporation. Started Mar 2008; status: terminated.
02
Drugs
lenalidomide
03
Conditions
T-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT00655668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00655668.